Inhibrx Biosciences, Inc.
HealthcareNASDAQ:INBX · NASDAQ Global Market
-$1.34 today
Vol 0.26M · Avg 0.43M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$1.3M of revenue converted into -$130.2M of net income for the selected period. Gross margin is 12.3% and net margin is -551.0%, showing how much revenue survives after costs and taxes. EPS is $-8.39, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M +550.0% | $200.0K -88.9% | $1.8M -17.9% | $2.2M -69.2% | $7.1M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.5M +8.7% | $2.3M +91.9% | $1.2M -98.9% | $110.2M +3999.2% | $2.7M | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$1.2M +43.3% | -$2.1M -442.4% | $609.0K +100.6% | -$108.0M -2533.9% | $4.4M | $8.9B | $7.6B | $6.2B |
| Gross Margin | -91.0% +951.5pp | -1042.5% -1076.3pp | 33.8% +4960.6pp | -4926.7% -4989.0pp | 62.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $113.0M -44.5% | $203.7M +6.9% | $190.6M +73.0% | $110.2M +54.2% | $71.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $23.3M -81.8% | $127.9M +335.3% | $29.4M +39.1% | $21.1M +71.0% | $12.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $133.8M -59.4% | $329.4M +49.8% | $219.8M +940.8% | $21.1M +71.2% | $12.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.5M +8.7% | $2.3M +91.9% | $1.2M -2.8% | $1.2M +2.5% | $1.2M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$132.5M -107.8% | $1.7B +924.1% | -$206.7M -64.3% | -$125.8M -66.9% | -$75.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -10195.5% -861870.5pp | 851675.0% +863157.9pp | -11482.9% -5743.1pp | -5739.8% -4682.0pp | -1057.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$135.0M +59.3% | -$331.4M -51.2% | -$219.2M -69.8% | -$129.1M -68.6% | -$76.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -10386.5% +155337.5pp | -165724.0% -153545.1pp | -12178.9% -6288.6pp | -5890.4% -4815.8pp | -1074.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $7.5M -31.0% | $10.9M -8.2% | $11.9M -26.0% | $16.1M +208.8% | $5.2M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $12.2M -9.6% | $13.5M -57.6% | $31.8M +97.7% | $16.1M +208.8% | $5.2M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$5.0M -100.2% | $2.0B +9947.4% | -$20.5M -27.3% | -$16.1M -209.6% | -$5.2M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$140.1M -108.3% | $1.7B +804.0% | -$239.7M -65.1% | -$145.2M -77.6% | -$81.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -10773.3% -854560.3pp | 843787.0% +857105.0pp | -13318.0% -6692.9pp | -6625.1% -5477.5pp | -1147.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $2.0K +0.0% | $2.0K -33.3% | $3.0K +0.0% | $3.0K +50.0% | $2.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$140.1M -108.3% | $1.7B +799.2% | -$241.4M -66.2% | -$145.2M -77.6% | -$81.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | -10773.5% -854559.5pp | 843786.0% +857194.9pp | -13408.9% -6783.7pp | -6625.3% -5477.7pp | -1147.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$9 -107.8% | $117 +2377.0% | -$5 -41.4% | -$4 -68.4% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$9 -107.8% | $117 +2377.0% | -$5 -41.4% | -$4 -68.4% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $15.5M +7.0% | $14.5M -69.3% | $47.1M +17.5% | $40.1M +5.5% | $38.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $15.5M +7.0% | $14.5M -69.3% | $47.1M +17.5% | $40.1M +5.5% | $38.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Enliven Therapeutics, Inc.
NASDAQ:ELVN
$2.81B
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.59B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.62B
Atai Beckley Inc.
NASDAQ:ATAI
$1.44B
Immatics N.V.
NASDAQ:IMTX
$1.26B
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
$1.21B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
CureVac N.V.
CVAC
$1.05B
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$856.09M
Sana Biotechnology, Inc.
NASDAQ:SANA
$745.82M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does INBX generate?
Inhibrx Biosciences, Inc. (INBX) reported $1.30M of revenue in fiscal 2025.
Is INBX profitable?
Inhibrx Biosciences, Inc. (INBX) reported -$140,055,000.00 of net income, with a net margin of -10773.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.